dc.creatorANDRESEN,MAX
dc.creatorREGUEIRA,TOMÁS
dc.date2010-07-01
dc.date.accessioned2017-03-07T16:29:02Z
dc.date.available2017-03-07T16:29:02Z
dc.identifierhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872010000700015
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/402371
dc.descriptionMyocardial dysfunction appears in 25% of patients with severe sepsis and in 50% of patients with septic shock, even in the presence of hyper dynamic states. It is characterized by a reduction in left ventricle ejection fraction, that reverts at the seventh to tenth day of evolution. Right ventricular dysfunction and diastolic left ventricular dysfunction can also appear. There is no consensus if an increase in end diastolic volume is part of the syndrome. High troponin or brain natriuretic peptide levels are associated with myocardial dysfunction and a higher mortality. The pathogenesis of myocardial dysfunction is related to micro and macro circulatory changes, infammatory response, oxidative stress, intracellular calcium management disturbances, metabolic changes, autonomic dysfunction, activation of apoptosis, mitochondrial abnormalities and a derangement in catecholaminergic stimulation. Since there is no specifc treatment for myocardial dysfunction, its management requires an adequate multi systemic support to maintain perfusion pressures and systemic fows suffcient for the regional and global demands.
dc.formattext/html
dc.languagees
dc.publisherSociedad Médica de Santiago
dc.sourceRevista médica de Chile v.138 n.7 2010
dc.subjectCardiomyopathies
dc.subjectHeart failure
dc.subjectSepsis
dc.titleDisfunción miocárdica en la sepsis
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución